Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens

Kathryn Anastos, Dalian Lu, Qiuhu Shi, Phyllis C. Tien, Robert C. Kaplan, Nancy A. Hessol, Steven Cole, Cheryl Vigen, Mardge Cohen, Mary Young, Jessica Justman

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

BACKGROUND: The effects of HIV infection, highly active antiretroviral therapy (HAART), and specific antiretroviral agents on lipoproteins in women are not well described. METHODS: In a cross-sectional substudy of the Women's Interagency HIV Study with 623 HIV-negative and 1556 HIV-positive women (636 untreated, 419 on non-protease inhibitor [PI] HAART, and 501 on PI-containing HAART), we performed multivariate analyses of associations among fasting lipoprotein levels, HIV infection, and HAART. RESULTS: Untreated HIV-positive women had lower high-density lipoprotein cholesterol (HDL-C) and higher triglycerides (TGs) but not lower low-density lipoprotein cholesterol (LDL-C) than HIV-negative women and were the most likely to have unfavorable HDL-C by National Cholesterol Education Program (NCEP) guidelines. PI HAART users had higher LDL-C than untreated HIV-infected women (107 vs. 100 mg/dL, P = 0.0006) and were the most likely to have unfavorable LDL-C and TGs by NCEP guidelines. HIV-negative women and non-PI HAART users had similar HDL-C levels (55 and 53 mg/dL, respectively), which were higher than those in untreated HIV-infected women and PI HAART users (42 and 49 mg/dL, respectively; P < 0.001 for all). Lamivudine, didanosine, nevirapine, and efavirenz were independently associated with higher HDL-C (P < 0.001 for all). Ritonavir, indinavir/ritonavir, and nelfinavir were associated with higher LDL-C (P < 0.01 for all). Stavudine, abacavir, and all ritonavir-containing regimens were associated with higher TGs (P < 0.05 for all), and tenofovir was associated with lower TGs (P = 0.009). CONCLUSIONS: A dyslipidemic pattern was associated with HIV infection itself, was more severe in users of PI-containing HAART, but was not present in women taking non-PI HAART.

Original languageEnglish (US)
Pages (from-to)34-42
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume45
Issue number1
DOIs
StatePublished - May 2007

Fingerprint

Anti-Retroviral Agents
Highly Active Antiretroviral Therapy
HIV
Lipids
HDL Cholesterol
Serum
Protease Inhibitors
Ritonavir
LDL Cholesterol
HIV Infections
Triglycerides
Therapeutics
Tenofovir
efavirenz
Lipoproteins
Cholesterol
Nelfinavir
Guidelines
Indinavir
Stavudine

Keywords

  • High-density lipoprotein
  • Highly active antiretroviral therapy
  • Lipids
  • Low-density lipoprotein
  • Women

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. / Anastos, Kathryn; Lu, Dalian; Shi, Qiuhu; Tien, Phyllis C.; Kaplan, Robert C.; Hessol, Nancy A.; Cole, Steven; Vigen, Cheryl; Cohen, Mardge; Young, Mary; Justman, Jessica.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 45, No. 1, 05.2007, p. 34-42.

Research output: Contribution to journalArticle

Anastos, Kathryn ; Lu, Dalian ; Shi, Qiuhu ; Tien, Phyllis C. ; Kaplan, Robert C. ; Hessol, Nancy A. ; Cole, Steven ; Vigen, Cheryl ; Cohen, Mardge ; Young, Mary ; Justman, Jessica. / Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. In: Journal of Acquired Immune Deficiency Syndromes. 2007 ; Vol. 45, No. 1. pp. 34-42.
@article{f8e7feae3c2449b782deb632cc7180ba,
title = "Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens",
abstract = "BACKGROUND: The effects of HIV infection, highly active antiretroviral therapy (HAART), and specific antiretroviral agents on lipoproteins in women are not well described. METHODS: In a cross-sectional substudy of the Women's Interagency HIV Study with 623 HIV-negative and 1556 HIV-positive women (636 untreated, 419 on non-protease inhibitor [PI] HAART, and 501 on PI-containing HAART), we performed multivariate analyses of associations among fasting lipoprotein levels, HIV infection, and HAART. RESULTS: Untreated HIV-positive women had lower high-density lipoprotein cholesterol (HDL-C) and higher triglycerides (TGs) but not lower low-density lipoprotein cholesterol (LDL-C) than HIV-negative women and were the most likely to have unfavorable HDL-C by National Cholesterol Education Program (NCEP) guidelines. PI HAART users had higher LDL-C than untreated HIV-infected women (107 vs. 100 mg/dL, P = 0.0006) and were the most likely to have unfavorable LDL-C and TGs by NCEP guidelines. HIV-negative women and non-PI HAART users had similar HDL-C levels (55 and 53 mg/dL, respectively), which were higher than those in untreated HIV-infected women and PI HAART users (42 and 49 mg/dL, respectively; P < 0.001 for all). Lamivudine, didanosine, nevirapine, and efavirenz were independently associated with higher HDL-C (P < 0.001 for all). Ritonavir, indinavir/ritonavir, and nelfinavir were associated with higher LDL-C (P < 0.01 for all). Stavudine, abacavir, and all ritonavir-containing regimens were associated with higher TGs (P < 0.05 for all), and tenofovir was associated with lower TGs (P = 0.009). CONCLUSIONS: A dyslipidemic pattern was associated with HIV infection itself, was more severe in users of PI-containing HAART, but was not present in women taking non-PI HAART.",
keywords = "High-density lipoprotein, Highly active antiretroviral therapy, Lipids, Low-density lipoprotein, Women",
author = "Kathryn Anastos and Dalian Lu and Qiuhu Shi and Tien, {Phyllis C.} and Kaplan, {Robert C.} and Hessol, {Nancy A.} and Steven Cole and Cheryl Vigen and Mardge Cohen and Mary Young and Jessica Justman",
year = "2007",
month = "5",
doi = "10.1097/QAI.0b013e318042d5fe",
language = "English (US)",
volume = "45",
pages = "34--42",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens

AU - Anastos, Kathryn

AU - Lu, Dalian

AU - Shi, Qiuhu

AU - Tien, Phyllis C.

AU - Kaplan, Robert C.

AU - Hessol, Nancy A.

AU - Cole, Steven

AU - Vigen, Cheryl

AU - Cohen, Mardge

AU - Young, Mary

AU - Justman, Jessica

PY - 2007/5

Y1 - 2007/5

N2 - BACKGROUND: The effects of HIV infection, highly active antiretroviral therapy (HAART), and specific antiretroviral agents on lipoproteins in women are not well described. METHODS: In a cross-sectional substudy of the Women's Interagency HIV Study with 623 HIV-negative and 1556 HIV-positive women (636 untreated, 419 on non-protease inhibitor [PI] HAART, and 501 on PI-containing HAART), we performed multivariate analyses of associations among fasting lipoprotein levels, HIV infection, and HAART. RESULTS: Untreated HIV-positive women had lower high-density lipoprotein cholesterol (HDL-C) and higher triglycerides (TGs) but not lower low-density lipoprotein cholesterol (LDL-C) than HIV-negative women and were the most likely to have unfavorable HDL-C by National Cholesterol Education Program (NCEP) guidelines. PI HAART users had higher LDL-C than untreated HIV-infected women (107 vs. 100 mg/dL, P = 0.0006) and were the most likely to have unfavorable LDL-C and TGs by NCEP guidelines. HIV-negative women and non-PI HAART users had similar HDL-C levels (55 and 53 mg/dL, respectively), which were higher than those in untreated HIV-infected women and PI HAART users (42 and 49 mg/dL, respectively; P < 0.001 for all). Lamivudine, didanosine, nevirapine, and efavirenz were independently associated with higher HDL-C (P < 0.001 for all). Ritonavir, indinavir/ritonavir, and nelfinavir were associated with higher LDL-C (P < 0.01 for all). Stavudine, abacavir, and all ritonavir-containing regimens were associated with higher TGs (P < 0.05 for all), and tenofovir was associated with lower TGs (P = 0.009). CONCLUSIONS: A dyslipidemic pattern was associated with HIV infection itself, was more severe in users of PI-containing HAART, but was not present in women taking non-PI HAART.

AB - BACKGROUND: The effects of HIV infection, highly active antiretroviral therapy (HAART), and specific antiretroviral agents on lipoproteins in women are not well described. METHODS: In a cross-sectional substudy of the Women's Interagency HIV Study with 623 HIV-negative and 1556 HIV-positive women (636 untreated, 419 on non-protease inhibitor [PI] HAART, and 501 on PI-containing HAART), we performed multivariate analyses of associations among fasting lipoprotein levels, HIV infection, and HAART. RESULTS: Untreated HIV-positive women had lower high-density lipoprotein cholesterol (HDL-C) and higher triglycerides (TGs) but not lower low-density lipoprotein cholesterol (LDL-C) than HIV-negative women and were the most likely to have unfavorable HDL-C by National Cholesterol Education Program (NCEP) guidelines. PI HAART users had higher LDL-C than untreated HIV-infected women (107 vs. 100 mg/dL, P = 0.0006) and were the most likely to have unfavorable LDL-C and TGs by NCEP guidelines. HIV-negative women and non-PI HAART users had similar HDL-C levels (55 and 53 mg/dL, respectively), which were higher than those in untreated HIV-infected women and PI HAART users (42 and 49 mg/dL, respectively; P < 0.001 for all). Lamivudine, didanosine, nevirapine, and efavirenz were independently associated with higher HDL-C (P < 0.001 for all). Ritonavir, indinavir/ritonavir, and nelfinavir were associated with higher LDL-C (P < 0.01 for all). Stavudine, abacavir, and all ritonavir-containing regimens were associated with higher TGs (P < 0.05 for all), and tenofovir was associated with lower TGs (P = 0.009). CONCLUSIONS: A dyslipidemic pattern was associated with HIV infection itself, was more severe in users of PI-containing HAART, but was not present in women taking non-PI HAART.

KW - High-density lipoprotein

KW - Highly active antiretroviral therapy

KW - Lipids

KW - Low-density lipoprotein

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=34247630552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247630552&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e318042d5fe

DO - 10.1097/QAI.0b013e318042d5fe

M3 - Article

C2 - 17460470

AN - SCOPUS:34247630552

VL - 45

SP - 34

EP - 42

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 1

ER -